KEY ELIGIBILITY CRITERIA

        Inclusion Criteria:

          1. Adults ≥ 18 years of age at the time of study consent

          2. Subjects with any of the following eligible solid tumor diagnoses as confirmed by
             cytology or histology:

               1. Escalation Cohorts (Part A): Subjects with solid tumors from pre-specified tumor
                  types (head and neck cancer, gynecological cancers [including ovarian,
                  endometrial, cervix, vagina, vulva], pancreatic [adenocarcinoma], lung
                  [adenocarcinoma and squamous cell carcinoma], gastric [adenocarcinoma MSIlow and
                  CPI refractory MSIhigh ], breast [Triple Negative Breast Cancer (TNBC) and
                  Hormone Receptor Positive Breast Cancer (HR+), HER-2 negative Breast Cancer
                  (HER-2-)] with metastatic disease that is relapsed or refractory to at least one
                  line of metastatic therapy (including a CPI-either alone or in combination- if
                  approved for that indication, and not eligible for other targeted therapies
                  specific for their tumor type). Lung adenocarcinoma subjects who are relapsed or
                  refractory to platinum-based chemotherapy in addition to prior treatment with
                  Programmed Cell Death-1 (PD-1)/Programmed Cell Death-Ligand 1 (PD-L1) or who give
                  informed consent to forego such therapy.

               2. Expansion Cohorts (Part B): Subjects with advanced solid tumors selected from
                  prespecified histologic subgroups identified in Part A, with TREM1 expression
                  confirmed by IHC (of fresh CNB) prior to enrollment. Lung adenocarcinoma subjects
                  who are relapsed or refractory to platinum-based chemotherapy in addition to
                  prior treatment with PD-1/PD-L1 or who give informed consent to forego such
                  therapy.

          3. Subjects must provide an original, diagnostic tumor sample to determine TREM1
             expression (Investigators have verified source and availability of archival tissue
             during screening). Subjects without an archival tissue sample will only be eligible if
             they choose and consent to provide a core needle biopsy of a metastatic lesion.

          4. Subjects must have documented disease progression

               1. Part A, including prior treatment with a CPI (alone or in combination), if
                  approved for that indication

               2. Part B, excluding refractory lung cancer patients who have progressed within 3
                  months of initiating chemotherapy-doublet regimens or lung cancer subjects who
                  have progressed within 6 months of initiation immunotherapy-chemotherapy
                  combination treatment

          5. Measurable disease by RECIST 1.1

          6. All acute toxic effects of any prior antitumor therapy, including immunotherapy,
             resolved to Grade ≤ 1 or < 2 if controlled on medications (e.g. thyroid replacement
             therapy) before the start of study drug dosing, except for alopecia, peripheral
             neuropathy, or hypothyroidism

          7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

        Exclusion Criteria:

          1. Patient is a candidate for molecularly targeted therapy (e.g. drugs targeting EGFR,
             EGFR, ALK, ROS-1, NTRK, MET, RET and BRAF V600E, Her2neu). Applies to enrolled
             subjects on both Part A and Part B of the study.

          2. History of autoimmune disorder requiring ongoing or intermittent disease-modifying
             therapy

          3. Untreated or uncontrolled brain metastases. (Treated, stable and asymptomatic
             metastases for at least 3 months prior to enrollment may be enrolled). Stable subjects
             with brain metastases receiving glucocorticoids must be on a stable dose for at least
             3 months prior to enrollment.

          4. Uncontrolled intercurrent illness including, but not limited to, active or chronic
             bleeding event within 28 days prior to first dose of study drug, or psychiatric
             illness/social situation that would limit compliance with study requirements as judged
             by treating physician

          5. Decompensated liver disease as evidenced by hepatic encephalopathy or coagulopathy

          6. Active angina or Class III or IV Congestive Heart Failure (CHF)(NYHA CHF Functional
             Classification System) or clinically significant cardiac disease within 12 months of
             first dose of study drug, including MI, unstable angina, Grade 2 or greater peripheral
             vascular disease, uncontrolled HTN, or arrhythmias not controlled by medication

          7. Any anti-cancer therapy, including small molecules, immunotherapy, chemotherapy,
             monoclonal antibody therapy, radiotherapy, or any other agents to treat cancer within
             14 days, of first dose of study drug. Subjects with a prior history of prostate cancer
             on LHRH agonist are eligible provided they have no evidence of metastatic disease.